poisar

Stocks · News reference

Bundeskartellamt Merger Control Filing Regarding Teledyne Technologies and Varex Imaging

Fiscal.ai

The German Federal Cartel Office (Bundeskartellamt) has recorded a merger control filing concerning the acquisition of Varex Imaging Corporation by Teledyne Technologies Incorporated.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncJuan Monteverde, Monteverde & Associates Pc

    EQUITY ALERT - IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger – BWMN, DV, VREX and HZO

    Monteverde & Associates PC, a class action securities firm, is investigating four merger deals to determine if they represent fair value for shareholders: Bowman Consulting Group's sale to Bernhard Capital Partners ($43.00/share), DoubleVerify Holdings' sale to Nielsen Holdings ($13.60/share), Varex Imaging's sale to Teledyne Technologies ($18.90/share), and MarineMax's sale to Francisco Partners ($53.00/share). The firm is soliciting shareholders to evaluate whether these proposed transactions are fair.

  2. Globenewswire IncHalper Sadeh Llc

    Halper Sadeh LLC is Investigating Whether VREX, BWMN, NATH, SYBX are Obtaining Fair Deals for their Shareholders

    Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers. The investigations cover Varex Imaging's sale to Teledyne Technologies, Bowman Consulting's sale to Bernhard Capital Partners, Nathan's Famous' sale to Smithfield Foods, and Synlogic's merger with Caldera Therapeutics.